For the quarter ended December 2025, Travere Therapeutics (TVTX) reported revenue of $129.69 million, up 73.4% over the same period last year. EPS came in at $0.03, compared to -$0.73 in the year-ago quarter.
The reported revenue represents a surprise of -8.97% over the Zacks Consensus Estimate of $142.46 million. With the consensus EPS estimate being $0.03, the EPS surprise was +16.73%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Travere performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Tiopronin products / Thiola: $23.27 million versus $21.9 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -2.6% change.
- Total net product sales: $126.61 million versus the six-analyst average estimate of $125.35 million. The reported number represents a year-over-year change of +72.2%.
- Revenue- FILSPARI: $103.34 million versus $103.05 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +108.2% change.
- Revenue- License and collaboration revenue: $3.08 million compared to the $15.33 million average estimate based on five analysts. The reported number represents a change of +148.3% year over year.
View all Key Company Metrics for Travere here>>>
Shares of Travere have returned -1.4% over the past month versus the Zacks S&P 500 composite's -0.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Travere Therapeutics, Inc. (TVTX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
